We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 24, 2020

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2–Low Expressing Advanced Breast Cancer

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
J. Clin. Oncol 2020 Feb 14;[EPub Ahead of Print], S Modi, H Park, RK Murthy, H Iwata, K Tamura, J Tsurutani, A Moreno-Aspitia, T Doi, Y Sagara, C Redfern, IE Krop, C Lee, Y Fujisaki, M Sugihara, L Zhang, J Shahidi, S Takahashi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading